2024
Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy
Lokeshwar S, Choksi A, Smani S, Kong V, Sundaresan V, Sutherland R, Brito J, Renzulli J, Sprenkle P, Leapman M. Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy. Urologic Oncology Seminars And Original Investigations 2024 PMID: 39521675, DOI: 10.1016/j.urolonc.2024.10.018.Peer-Reviewed Original ResearchMRI-TRUSMRI-TRUS fusionImage-guided biopsyFusion biopsyGG upgradingTRUS biopsyBiopsy strategyBiopsy typeNo significant differencePathological concordanceBiopsy techniqueHigh-resolution micro-ultrasoundMRI-TRUS fusion biopsyMultivariate logistic-regression analysisMRI fusion biopsySystematic transrectal ultrasoundProstate cancer patientsSignificant differenceMicro-ultrasoundLogistic-regression analysisMultivariable-analysisPathological downgradingPathological upgradingRandomized controlled trialsProstate biopsyInter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap?
Smani S, Jalfon M, Sundaresan V, Lokeshwar S, Nguyen J, Halstuch D, Khajir G, Cavallo J, Sprenkle P, Leapman M, Kim I. Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap? Urologic Oncology Seminars And Original Investigations 2024 PMID: 39438211, DOI: 10.1016/j.urolonc.2024.10.002.Peer-Reviewed Original ResearchClinically significant PCaPI-RADS scoreDetect clinically significant PCaReporting of prostate cancerInter-reader reliabilityProstate cancerPI-RADSDiagnostic accuracyReceiver operating characteristicInter-readerPresence of clinically significant PCaProstate Imaging Reporting & Data SystemDetect clinically significant diseasePI-RADS 3 lesionsTertiary academic care centerMRI fusion biopsyPI-RADS 3Significant PCaProstate cancer managementClinically significant diseaseInter-reader agreementSubgroup of lesionsAcademic care centerIntraclass correlationMpMRI interpretationLong-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease courseDiagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy
Press B, Lokeshwar S, Webb L, Khajir G, Smani S, Olawoyin O, Gardezi M, Rahman S, Leapman M, Sprenkle P. Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 1168-1176. PMID: 39465014, PMCID: PMC11502073, DOI: 10.37349/etat.2024.00269.Peer-Reviewed Original ResearchProstate Health IndexMRI-ultrasound fusion targeted biopsyClinically significant prostate cancerFusion targeted biopsyPI-RADS 1Gleason grade groupMagnetic resonance imagingPhi densityPI-RADSProstate specific-antigenProstate biopsyImproved detection of clinically significant prostate cancerDetection of clinically significant prostate cancerPHI testingProstate health index densityElevated prostate-specific antigenMRI-ultrasound fusionProstate Imaging ReportingSignificant prostate cancerProstate-specific antigenSelection of patientsDetection of PCaReceiver operating characteristic curveCombination of magnetic resonance imagingMultivariate logistic regressionAssociation Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting
Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Sprenkle P, Ross A. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. European Urology Oncology 2024 PMID: 39098389, DOI: 10.1016/j.euo.2024.07.010.Peer-Reviewed Original ResearchDecipher genomic classifierRisk of metastasisBiochemical recurrenceRadical prostatectomyGenomic classifierDecipher testProstate cancerProstate Risk Assessment Postsurgical ScoreRisk of biochemical recurrencePatient's prostate cancerRisk of cancer recurrencePathological risk factorsProstate cancer outcomesCox proportional hazards regressionRetrospective cohort studyElectronic health record dataReal-world settingsProportional hazards regressionHealth record dataReal-world practice settingsProstate biopsyRP specimensOncological outcomesPrognostic significanceMedian ageRisk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy
Smani S, Sundaresan V, Lokeshwar S, Choksi A, Carbonella J, Brito J, Renzulli J, Sprenkle P, Leapman M. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 981-996. PMID: 39280242, PMCID: PMC11390291, DOI: 10.37349/etat.2024.00259.Peer-Reviewed Original ResearchGleason score upgradingProstate-specific antigenRisk factorsMagnetic resonance imagingRadical prostatectomyScore upgradingAssociated with Gleason score upgradingBiopsy to radical prostatectomyHigher-risk prostate cancerPatients treated with surgeryProstate magnetic resonance imagingClinically localized diseaseGleason grade groupLow-risk diseaseRecognition of risk factorsBody mass indexGleason upgradingFinal pathologyProstate volumeProstate biopsySource of diagnostic uncertaintyBiopsy coresLocalized diseaseProstate cancerInitial managementAssociations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer
Sundaresan V, Wang R, Long J, Sprenkle P, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 11: 965-973. PMID: 39196719, DOI: 10.1097/upj.0000000000000679.Peer-Reviewed Original ResearchLocalized prostate cancerClinically localized prostate cancerHigh-risk diseaseProstate MRIProstate cancerTreatment intensificationIntensified treatmentGenomic testingTreated patientsProstate magnetic resonance imagingEnd Results databaseLong-term patient outcomesProstate cancer prognosisRetrospective cohort studyAssociated with decreased oddsRisk stratification toolPrimary study outcomeAssociated with increased oddsMagnetic resonance imagingResults databaseStratification toolTreatment patientsCohort studyRisk strataCancer prognosisProstate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement
Sundaresan V, Smani S, Rajwa P, Renzulli J, Sprenkle P, Kim I, Leapman M. Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Urologic Oncology Seminars And Original Investigations 2024 PMID: 39019723, DOI: 10.1016/j.urolonc.2024.06.003.Peer-Reviewed Original ResearchProstate specific antigenProstate cancerPSA-based prostate cancer screeningDiagnostic performanceProstate specific antigen densityProstate specific antigen velocityLow-grade prostate cancerProstate-specific antigen screeningFree prostate specific antigenTreatment of prostate cancerProstate cancer screeningClinical action thresholdsProstate volumeAntigen screeningMalignant cellsSpecific antigenCancer screeningScreening biomarkerProstateClinical roleTest characteristicsCancerClinical applicationClinical thresholdEarly detectionAssociation of Crowd-Sourced Assessment of Technical Skills (CSATSTM) and Outcomes of Robotic Assisted Radical Prostatectomy
Rabil M, Jalfon M, Heckscher D, Song Z, Li F, Martin T, Sprenkle P, Hesse D, Kim I, Leapman M, Cavallo J. Association of Crowd-Sourced Assessment of Technical Skills (CSATSTM) and Outcomes of Robotic Assisted Radical Prostatectomy. Urology 2024 PMID: 39019332, DOI: 10.1016/j.urology.2024.07.014.Peer-Reviewed Original ResearchRobotic-assisted laparoscopic prostatectomyCrowd-Sourced AssessmentGEARS scoreCrowd-sourced assessment of technical skillsRALP casesOutcomes of robot-assisted radical prostatectomyRobot-assisted radical prostatectomyExpert narrative reviewPelvic fluid collectionsPatient outcomesLikelihood of sepsisPost-operative outcomesAssociated with significant improvementsFellowship-trained urologistsAssessment of technical skillsRadical prostatectomyLaparoscopic prostatectomyAssociated with improvementsGlobal Evaluative AssessmentFluid collectionLogistic regression modelsSurgeon selectionPracticing surgeonsProstatectomySurgeonsRisk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy
Diaz G, Webb L, Rabil M, Lokeshwar S, Choksi A, Leapman M, Sprenkle P. Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy. Current Urology Reports 2024, 25: 243-252. PMID: 38896314, DOI: 10.1007/s11934-024-01220-w.Peer-Reviewed Original ResearchProstate biopsyRisk factorsEffective pain management strategiesDiagnosed prostate cancerPain management strategiesIn-office proceduresModern management optionsNonadherence to treatmentContemporary management optionsEnhance patient comfortInnovative imaging modalitiesExperience of painFusion biopsyProstate volumePain intensityProstate cancerPain varyPatient ageIncreased painFollow-upIn-officeManagement optionsSurveillance adherenceBiopsyPharmacological analgesicsDevelopment of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage
Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Ross A, Sprenkle P. Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. JAMA Network Open 2024, 7: e2417274. PMID: 38874922, PMCID: PMC11179136, DOI: 10.1001/jamanetworkopen.2024.17274.Peer-Reviewed Original ResearchConceptsElectronic health recordsCancer diagnosisClinical data linkageMedicine Clinical TermsPatterns of careProstate cancer diagnosisRadical prostatectomyCancer risk stratificationData linkageHealth recordsClinical dataMain OutcomesCancer outcomesClinical juncturesClinical careCommon Procedural Terminology codesAdministrative dataDiagnosis codesLongitudinal clinical dataCohort studyPharmacy recordsGenomic classifierProcedural Terminology codesDevelopment of prostate cancer metastasisLinkage dataMP19-12 CHARACTERISTICS OF PI-RADS 5 LESIONS WITH A NEGATIVE OR GLEASON GRADE GROUP 1 BIOPSY
Webb L, Diaz G, Velasquez E, Goberdhan S, Khajir G, Sundaresan V, Leapman M, Sprenkle P. MP19-12 CHARACTERISTICS OF PI-RADS 5 LESIONS WITH A NEGATIVE OR GLEASON GRADE GROUP 1 BIOPSY. Journal Of Urology 2024, 211: e315. DOI: 10.1097/01.ju.0001008716.22569.77.12.Peer-Reviewed Original ResearchMP19-16 INCORPORATING PROSTATE MRI IMAGING CHARACTERISTICS TO IMPROVE PROSTATE CANCER DIAGNOSIS AND RISK STRATIFICATION: AN ANALYSIS AND NOMOGRAM DERIVED FROM A 9,536 PATIENT, MULTI-INSTITUTIONAL COHORT
Shumaker L, Fang A, Kaneko M, Ramacciotti L, Prakash N, Das A, Patel H, Khajir G, Fan R, Wang S, Pineault K, Sidana A, Gupta G, Filson C, Wysock J, Siddiqui M, Sonn G, Sprenkle P, Ross A, Jarrard D, Punnen S, Abreu A, Rais-Bahrami S. MP19-16 INCORPORATING PROSTATE MRI IMAGING CHARACTERISTICS TO IMPROVE PROSTATE CANCER DIAGNOSIS AND RISK STRATIFICATION: AN ANALYSIS AND NOMOGRAM DERIVED FROM A 9,536 PATIENT, MULTI-INSTITUTIONAL COHORT. Journal Of Urology 2024, 211: e316. DOI: 10.1097/01.ju.0001008716.22569.77.16.Peer-Reviewed Original ResearchMP19-09 PREDICTORS OF A POSITIVE BIOPSY FOLLOWING A PIRADS 3 FINDING ON MRI
Diaz G, Webb L, Khajir G, Sprenkle P. MP19-09 PREDICTORS OF A POSITIVE BIOPSY FOLLOWING A PIRADS 3 FINDING ON MRI. Journal Of Urology 2024, 211: e313. DOI: 10.1097/01.ju.0001008716.22569.77.09.Peer-Reviewed Original ResearchMP31-04 HOW DO 5-ALPHA-REDUCTASE INHIBITORS CHANGE PSA DENSITY IN PATIENTS ON ACTIVE SURVEILLANCE?
Webb L, Diaz G, Rahman S, Khajir G, Sprenkle P. MP31-04 HOW DO 5-ALPHA-REDUCTASE INHIBITORS CHANGE PSA DENSITY IN PATIENTS ON ACTIVE SURVEILLANCE? Journal Of Urology 2024, 211: e504. DOI: 10.1097/01.ju.0001008936.35187.0b.04.Peer-Reviewed Original ResearchPD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.Peer-Reviewed Original ResearchPD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.Peer-Reviewed Original ResearchMP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.Peer-Reviewed Original ResearchPD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES. Journal Of Urology 2024, 211: e972. DOI: 10.1097/01.ju.0001008792.09108.b4.11.Peer-Reviewed Original ResearchRISKS OF GRADE RECLASSIFICATION AMONG PATIENTS WITH GLEASON GRADE GROUP 1 PROSTATE CANCER AND PI-RADS 5 FINDINGS ON PROSTATE MRI
Sundaresan V, Webb L, Rabil M, Golos A, Sutherland R, Sprenkle P, Kim I, Leapman M. RISKS OF GRADE RECLASSIFICATION AMONG PATIENTS WITH GLEASON GRADE GROUP 1 PROSTATE CANCER AND PI-RADS 5 FINDINGS ON PROSTATE MRI. Urologic Oncology Seminars And Original Investigations 2024, 42: s79. DOI: 10.1016/j.urolonc.2024.01.222.Peer-Reviewed Original ResearchGleason Grade Group 1PI-RADS 5 lesionsPI-RADSProstate biopsyProstate cancerGleason upgradingRadical prostatectomyActive surveillanceProstate MRIMultivariate logistic regressionGrade Group 1 prostate cancerConversion to active treatmentOptimal management of patientsGrade group 1PI-RADS 5Gleason grade groupProstate Imaging ReportingDied of diseaseManagement of patientsLogistic regressionPrimary study outcomeAssociated with oddsMedian PSAMetastatic diseaseGrade disease